ANNOVIS Study of the Buntanetap Drug

About Buntanetap

Buntanetap is a small, orally available molecule that targets neurodegeneration by inhibiting the translation of neurotoxic aggregating proteins and thereby impeding the toxic cascade. This improves axonal transport, synaptic transmission, and reduces neuroinflammation, ultimately restoring the health of nerve cells and brain function. By normalizing these pathways, buntanetap has the potential to reverse neurodegeneration and improve quality of life for patients.

To learn more about the drug, and Annovis, visit the page below.

---

Study Timeline

18-month double-blind treatment period. The drug will be administered as an oral pill.

Inclusion Criteria

• 55 – 85 years old
• Mild Cognitive Impairment (MCI) or mild dementia due to Alzheimer’s Disease.
• Positive for amyloid beta as defined by plasma p-tau 217 at screening
• Mini-mental state examination 21 – 28 at screening and baseline
• Clinical dementia rating of 0.5 – 1 at screening and baseline
• AChEIs (medication side effects of abdominal pain, chest pain, headaches, eye problems, and severe leg pain) and memantine allowed if stable for at least 4 weeks prior to screening.

Exclusion Criteria

• Screening MRI abnormalities
• History of psychiatric disorders
• History of seizure disorders
• Cancer or malignant tumor within the past year
• Uncontrolled Type 1 or Type 2 diabetes
• Clinically significant abnormal laboratory values